Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.67 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.67 |
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947553 | 0.94 | S1PR1 (0.88) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2943601 | 0.94 | S1PR1 (0.88) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2948150 | 0.93 | S1PR1 (1.00) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2943358 | 0.92 | S1PR1 (0.89) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2951221 | 0.92 | S1PR1 (0.84) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2946083 | 0.92 | S1PR1 (0.94) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2944809 | 0.92 | S1PR1 (0.91) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2944012 | 0.92 | S1PR1 (0.84) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL4687480 | 0.91 | S1PR1 (0.82) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 | |
| SCHEMBL2947804 | 0.91 | S1PR1 (0.82) | S1PR1CACNA1GCACNA1HCACNA1IS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4807884-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | claimed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | claimed |
| EP-1805163-A2 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA¬A|PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-07-11 | — | — | EP | claimed |
| WO-2006010544-A2 | 1, 1A, 5, 5A-TETRAHYDRO-3-THIA-CYCLOPROPA’A! PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-02-02 | — | — | WO | claimed |
| WO-2006010379-A1 | NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-02-02 | — | — | WO | claimed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | disclosed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | disclosed |
| WO-2006010379-A1 | NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064740-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | S1PR1 1258/4885CACNA1G 3634/4885CACNA1H 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.